PortalPublikationenCD57 expression in incidental, clinically manifest, and meta...

CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate

Standard

CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. / Wangerin, Holger; Kristiansen, Glen; Schlomm, Thorsten; Stephan, Carsten; Gunia, Sven; Zimpfer, Annette; Weichert, Wilko; Sauter, Guido; Erbersdobler, Andreas.

in: BIOMED RES INT , Jahrgang 2014, 22.05.2014, S. 356427.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wangerin, H, Kristiansen, G, Schlomm, T, Stephan, C, Gunia, S, Zimpfer, A, Weichert, W, Sauter, G & Erbersdobler, A 2014, 'CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate', BIOMED RES INT , Jg. 2014, S. 356427. https://doi.org/10.1155/2014/356427

APA

Wangerin, H., Kristiansen, G., Schlomm, T., Stephan, C., Gunia, S., Zimpfer, A., Weichert, W., Sauter, G., & Erbersdobler, A. (2014). CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. BIOMED RES INT , 2014, 356427. https://doi.org/10.1155/2014/356427

Vancouver

Wangerin H, Kristiansen G, Schlomm T, Stephan C, Gunia S, Zimpfer A et al. CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate. BIOMED RES INT . 2014 Mai 22;2014:356427. https://doi.org/10.1155/2014/356427

Bibtex

@article{ff7d8f18163d481397461cf9dd53e716,
title = "CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate",
abstract = "OBJECTIVES: CD57 is normally found on NK-cells, but little is known about its expression in prostatic tissue.METHODS: We investigated CD57 expression by immunohistochemistry using tissue microarrays containing 3262 prostate cancers (PCa), lymph node metastases, and benign prostatic tissue. The results were compared with clinical and pathological parameters.RESULTS: Overall, 87% of PCa showed a moderate or strong expression of CD57. There was no significant difference to corresponding benign prostatic tissue. CD57 was increasingly lost from incidental over clinically manifest cancers to metastases. It correlated significantly with Gleason grade and pT-category, but not with PSA tissue expression. Loss of CD57 expression was an independent risk factor for PSA recurrence after prostatectomy in a multivariate Cox regression analysis. In standard sections, CD57 expression was heterogeneous, especially in large, high-grade PCa.CONCLUSIONS: There is a peculiar expression of CD57 in PCa and benign prostatic tissue. CD57 loss is associated with tumor dedifferentiation and tumor size. However, the use of this marker for prognostic purposes is hampered by its heterogeneous expression.",
author = "Holger Wangerin and Glen Kristiansen and Thorsten Schlomm and Carsten Stephan and Sven Gunia and Annette Zimpfer and Wilko Weichert and Guido Sauter and Andreas Erbersdobler",
year = "2014",
month = may,
day = "22",
doi = "10.1155/2014/356427",
language = "English",
volume = "2014",
pages = "356427",
journal = "BIOMED RES INT ",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

RIS

TY - JOUR

T1 - CD57 expression in incidental, clinically manifest, and metastatic carcinoma of the prostate

AU - Wangerin, Holger

AU - Kristiansen, Glen

AU - Schlomm, Thorsten

AU - Stephan, Carsten

AU - Gunia, Sven

AU - Zimpfer, Annette

AU - Weichert, Wilko

AU - Sauter, Guido

AU - Erbersdobler, Andreas

PY - 2014/5/22

Y1 - 2014/5/22

N2 - OBJECTIVES: CD57 is normally found on NK-cells, but little is known about its expression in prostatic tissue.METHODS: We investigated CD57 expression by immunohistochemistry using tissue microarrays containing 3262 prostate cancers (PCa), lymph node metastases, and benign prostatic tissue. The results were compared with clinical and pathological parameters.RESULTS: Overall, 87% of PCa showed a moderate or strong expression of CD57. There was no significant difference to corresponding benign prostatic tissue. CD57 was increasingly lost from incidental over clinically manifest cancers to metastases. It correlated significantly with Gleason grade and pT-category, but not with PSA tissue expression. Loss of CD57 expression was an independent risk factor for PSA recurrence after prostatectomy in a multivariate Cox regression analysis. In standard sections, CD57 expression was heterogeneous, especially in large, high-grade PCa.CONCLUSIONS: There is a peculiar expression of CD57 in PCa and benign prostatic tissue. CD57 loss is associated with tumor dedifferentiation and tumor size. However, the use of this marker for prognostic purposes is hampered by its heterogeneous expression.

AB - OBJECTIVES: CD57 is normally found on NK-cells, but little is known about its expression in prostatic tissue.METHODS: We investigated CD57 expression by immunohistochemistry using tissue microarrays containing 3262 prostate cancers (PCa), lymph node metastases, and benign prostatic tissue. The results were compared with clinical and pathological parameters.RESULTS: Overall, 87% of PCa showed a moderate or strong expression of CD57. There was no significant difference to corresponding benign prostatic tissue. CD57 was increasingly lost from incidental over clinically manifest cancers to metastases. It correlated significantly with Gleason grade and pT-category, but not with PSA tissue expression. Loss of CD57 expression was an independent risk factor for PSA recurrence after prostatectomy in a multivariate Cox regression analysis. In standard sections, CD57 expression was heterogeneous, especially in large, high-grade PCa.CONCLUSIONS: There is a peculiar expression of CD57 in PCa and benign prostatic tissue. CD57 loss is associated with tumor dedifferentiation and tumor size. However, the use of this marker for prognostic purposes is hampered by its heterogeneous expression.

U2 - 10.1155/2014/356427

DO - 10.1155/2014/356427

M3 - SCORING: Journal article

C2 - 24977150

VL - 2014

SP - 356427

JO - BIOMED RES INT

JF - BIOMED RES INT

SN - 2314-6133

ER -